Overview

Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This study is to designed to test the role of complement in the late asthmatic response to allergen challenge in mild asthma, as an indicator of the possible role of complement in the broader asthmatic population.
Phase:
Phase 2
Details
Lead Sponsor:
Alexion Pharmaceuticals
Treatments:
Eculizumab